Nick Crabb explains the UK’s health technology assessment agency's (NICE's) approach to cell and gene therapies.

Regardless of how Britain leaves the European Union, the global pharma industry must always lobby for positive change.

Douglas J. Swirsky, CEO of Rexahn Pharmaceuticals, explains his company’s approach to developing more effective cancer treatments.

The Medicine Maker speaks with Jeanne Thoma, President and CEO from SPI Pharma

The Medicine Maker speaks with Christophe Le Ret, Global Marketing Director of Umicore

No-deal Brexit poses unique challenges for the development and advanced therapy sectors, not least tight timelines and a limited ability to stockpile.

The Medicine Maker speaks with Michel Legarde, President of Pharmaceutical Services, Patheon, part of Thermo Fisher Scientific.

The Medicine Maker speaks with Nick Shackley, VP of Johnson Matthey

The Medicine Maker speaks with Angela Strzelecki, Global Business Director of Dupont

The Medicine Maker speaks with Oskar Gold of Vetter